| # | Title | Journal | Year | Citations |
|---|
| 1 | Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine | 2016 | 1,036 |
| 2 | Investigation of the Safety of Irreversible Electroporation in Humans | Journal of Vascular and Interventional Radiology | 2011 | 408 |
| 3 | Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study | Lancet, The | 2017 | 307 |
| 4 | Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer | Annals of Oncology | 2019 | 141 |
| 5 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study | Lancet Oncology, The | 2021 | 132 |
| 6 | Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype | Modern Pathology | 2013 | 127 |
| 7 | Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype | International Journal of Cancer | 2018 | 83 |
| 8 | Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies | International Journal of Cancer | 2021 | 77 |
| 9 | A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma | Annals of Oncology | 2015 | 67 |
| 10 | Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma | Journal of Clinical Oncology | 2023 | 62 |
| 11 | The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study | Social Science and Medicine | 2009 | 38 |
| 12 | Metastatic pathways in patients with cutaneous melanoma | Pigment Cell and Melanoma Research | 2017 | 38 |
| 13 | Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer | British Journal of Cancer | 2007 | 35 |
| 14 | Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy | | 2021 | 34 |
| 15 | Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma | Cancer Immunology, Immunotherapy | 2015 | 31 |
| 16 | Second medical opinions: the views of oncology patients and their physicians | Supportive Care in Cancer | 2010 | 30 |
| 17 | Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders | | 2021 | 30 |
| 18 | Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis | British Journal of Cancer | 2021 | 27 |
| 19 | Central Nervous System Lymphoma: Primary Lumbar Nerve Root Infiltration | Acta Haematologica | 1989 | 23 |
| 20 | Metastatic colorectal cancer to a primary thyroid cancer | World Journal of Surgical Oncology | 2008 | 16 |
| 21 | The acceleration of ageing in older patients with cancer | Journal of Geriatric Oncology | 2021 | 14 |
| 22 | The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis | European Journal of Cancer | 2021 | 12 |
| 23 | Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology | Current Oncology Reports | 2022 | 11 |
| 24 | An update on adjuvant systemic therapies in melanoma | Melanoma Management | 2019 | 10 |
| 25 | Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies | British Journal of Cancer | 2022 | 10 |
| 26 | Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995–2009 | Internal Medicine Journal | 2013 | 9 |
| 27 | 18F-fluorodeoxyglucose positron emission tomography-positive sarcoidosis after chemoradiotherapy for Hodgkin’s disease: a case report | Journal of Medical Case Reports | 2011 | 8 |
| 28 | Prognosis associated with cutaneous melanoma metastases | Australasian Journal of Dermatology | 2015 | 8 |
| 29 | Diet and risk of gastro-oesophageal reflux disease in the Melbourne Collaborative Cohort Study | Public Health Nutrition | 2021 | 8 |
| 30 | Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies | International Journal of Cancer | 2021 | 7 |
| 31 | Effect of direct-current magnetic field on the specific absorption rate of metamagnetic CoMnSi: A potential approach to switchable hyperthermia therapy | AIP Advances | 2020 | 6 |
| 32 | Factors Explaining Socio-Economic Inequalities in Survival from Colon Cancer: A Causal Mediation Analysis | Cancer Epidemiology Biomarkers and Prevention | 2021 | 4 |
| 33 | The blood-brain barrier and response of C.N.S. metastases to chemotherapy | Journal of Neuro-Oncology | 1989 | 3 |
| 34 | The Victorian Melanoma Service: A 20‐year review of an Australian multidisciplinary cancer service | Australasian Journal of Dermatology | 2016 | 3 |
| 35 | Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis | Immunotherapy | 2020 | 3 |
| 36 | Prediagnosis alcohol intake and metachronous cancer risk in cancer survivors: A prospective cohort study | International Journal of Cancer | 2021 | 2 |
| 37 | Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply | Lancet Oncology, The | 2021 | 2 |
| 38 | Dramatic clinical response in the treatment of small cell glioblastoma multiforme | Journal of Clinical Pharmacy and Therapeutics | 2022 | 2 |
| 39 | 138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors | Annals of Oncology | 2021 | 2 |
| 40 | Immune checkpoint inhibitors and the risk of major atherosclerotic cardiovascular events in patients with high-risk or advanced melanoma: a retrospective cohort study | Cardio-Oncology | 2022 | 2 |
| 41 | Progression-free survival and recurrence results for AGITG DOCTOR: Pre-op cisplatin, 5FU & DOCetaxel +/-radiotherapy after poor early response to cisplatin & 5FU for resectable oesophageal adenocarcinoma | Annals of Oncology | 2018 | 1 |
| 42 | 1080MO The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition | Annals of Oncology | 2020 | 1 |
| 43 | Caution in the age of optimism; a salient lesson in advanced melanoma | Annals of Translational Medicine | 2020 | 1 |
| 44 | 981P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors | Annals of Oncology | 2021 | 1 |
| 45 | Cancer Treatment Patterns and Factors Affecting Receipt of Treatment in Older Adults: Results from the ASPREE Cancer Treatment Substudy (ACTS) | Cancers | 2023 | 1 |
| 46 | PD-1 blockade in renal transplant patients with poor prognosis cancer and minimizing risk of organ rejection using comprehensive immune monitoring and screening techniques: A safety study | Annals of Oncology | 2018 | 0 |
| 47 | 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma | Annals of Oncology | 2020 | 0 |
| 48 | 783Lifetime alcohol intake and stomach cancer risk: a pooled analysis of two prospective cohort studies | International Journal of Epidemiology | 2021 | 0 |
